EQS-News
Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
- Evotec, Yonsei, Zymedi get $4.5M grant for lung treatments.
- Funding aims to develop antibodies for asthma, IPF.
- Collaboration targets novel tRNA synthetase therapies.

EQS-News: Evotec SE / Key word(s): Miscellaneous
Hamburg, Germany, 22 January 2025: “We are excited to work together with Prof. Sunghoon Kim and our colleagues at Zymedi and Yonsei University to cooperatively advance a particularly promising approach to develop novel antibody-based treatments for asthma and IPF,” said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. “The synergies between the three parties supported by the KIAT grant showcase how international collaborations can help accelerate the development of novel therapies for diseases with a high unmet medical need: Dr. Kim’s laboratory at Yonsei University has been recognized as a global leader in the field of tRNA synthetases by uncovering their diverse regulatory activities for body homeostasis. Zymedi is an aspiring Korean company translating the pathologic association of tRNA synthetases to new medicine. Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development of fibrosis and lung diseases. We are grateful to the Korean government and honored to be part of this outstanding consortium” Diskutieren Sie über die enthaltenen Werte |